Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus.
Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus.
复制标题
DOI：
10.3899/jrheum.090994
复制
发表时间：
2010-06
期刊：
影响因子：
--
通讯作者：
Wasko MC
中科院分区：
文献类型：
--
作者：
Penn SK;Kao AH;Schott LL;Elliott JR;Toledo FG;Kuller L;Manzi S;Wasko MC
旨在确定患有系统性红斑狼疮 (SLE) 或类风湿性关节炎 (RA) 的非糖尿病女性当前使用羟氯喹 (HCQ) 与血糖控制的 2 项指标（空腹血糖和胰岛素敏感性）之间的关系。 2000 年至 2005 年间招募的患有 SLE (n = 149) 或 RA (n = 177) 的非糖尿病女性进行心血管危险因素的横断面评估，以 HCQ 使用状况为特征。对特定疾病组的 HCQ 使用者和非使用者的未调整和多变量调整平均空腹血糖、中值胰岛素和胰岛素抵抗 [通过稳态模型评估 (HOMA-IR) 计算进行评估] 进行比较。患有 SLE 的女性比患有 RA 的女性更多地服用 HCQ（48% vs 18%；p < 0.0001；平均剂量 ~ 400 mg vs ~ 200 mg）。对于患有 SLE 或 RA 的女性，在调整年龄、腰围、病程、泼尼松剂量、C 反应蛋白、绝经状态、非甾体抗炎药和疾病特异性指标后，HCQ 使用者的血糖低于非使用者（SLE：85.9 vs 89.3 mg/dl，p = 0.04；RA：82.5 vs 86.6 mg/dl，p = 0.05）。在患有 SLE 的女性中，使用 HCQ 也与较低的 logHOMA-IR 相关（0.97 vs 1.12，p = 0.09）；在患有 RA 的患者中，logHOMA-IR 没有发现差异。在两组患者中，HCQ 的使用与空腹胰岛素水平均无关。 HCQ 的使用与 SLE 或 RA 女性的空腹血糖降低相关，并且 SLE 组的 logHOMA-IR 降低相关。使用 HCQ 可能有助于通过改善这些患者的血糖控制来降低心血管风险。
To determine the relationship between current hydroxychloroquine (HCQ) use and 2 indicators of glycemic control, fasting glucose and insulin sensitivity, in nondiabetic women with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). Nondiabetic women with SLE (n = 149) or RA (n = 177) recruited between 2000 and 2005 for a cross-sectional evaluation of cardiovascular risk factors were characterized by HCQ usage status. Unadjusted and multivariately adjusted mean fasting glucose, median insulin, and insulin resistance [assessed by the homeostasis model assessment (HOMA-IR) calculation] were compared among HCQ users and nonusers for disease-specific groups. More women with SLE were taking HCQ than those with RA (48% vs 18%; p < 0.0001; mean dose ~ 400 mg vs ~ 200 mg). For women with SLE or RA, after adjustment for age, waist circumference, disease duration, prednisone dosage, C-reactive protein, menopausal status, nonsteroidal antiinflammatory drugs, and disease-specific indicators, serum glucose was lower in HCQ users than in nonusers (SLE: 85.9 vs 89.3 mg/dl, p = 0.04; RA: 82.5 vs 86.6 mg/dl, p = 0.05). In women with SLE, HCQ use also was associated with lower logHOMA-IR (0.97 vs 1.12, p = 0.09); in those with RA, no differences in logHOMA-IR were seen. HCQ usage was not associated with fasting insulin levels in either patient group. HCQ use was associated with lower fasting glucose in women with SLE or RA and also lower logHOMA-IR in the SLE group. The use of HCQ may be beneficial for reducing cardiovascu lar risk by improving glycemic control in these patients.
登录
查看更多内容
影响因子：
27.4
作者：
Doria, A;Shoenfeld, Y;Pauletto, P
通讯作者：
Pauletto, P
影响因子：
5.3
作者：
Chung, Cecilia P.;Oeser, Annette;Stein, C. Michael
通讯作者：
Stein, C. Michael
影响因子：
8.2
作者：
MATTHEWS, DR;HOSKER, JP;TURNER, RC
通讯作者：
TURNER, RC
影响因子：
--
作者：
Bruce, IN;Urowitz, MB;Steiner, G
通讯作者：
Steiner, G
影响因子：
--
作者：
POWRIE, JK;SMITH, GD;JONES, RH
通讯作者：
JONES, RH